Saturday, October 31, 2026

EUR/CHF Bearish Momentum: 0.83% Down In The Last 5 Sessions

ViaNews Editorial Team

October 1, 2024

EUR/CHF Bearish Momentum: 0.83% Down In The Last 5 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 0.83% for the last 5 sessions. At 13:06 EST on Tuesday, 1 October, EUR/CHF (EURCHF) is $0.93.

EUR/CHF's yearly highs and lows, it's 3.511% up from its 52-week low and 5.871% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.02%, a positive 0.01%, and a positive 0.31%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.31% (last week), 0.27% (last month), and 0.31% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Monday, 30 September, "In terms of support, the USD/JPY pair may navigate around the 139.58 region, the lowest point since June 2023.", "On the upside, a return to the ascending channel could weaken the bearish case and lead the USD/JPY pair to test the nine-day Exponential Moving Average (EMA) at the 143.10 level. "
  • According to FXStreet on Monday, 30 September, "Just as hopes were building that some of the recent volatility in USD/JPY was on course to die-back, Japanese political change has proved that the currency pair maintains a nervous disposition, Rabobank's FX strategist Jane Foley notes.", "Despite the changing political landscape both the Japan and in the US, we would expect central bank policy to remain the primary driver of USD/JPY over the coming months. "
  • Usd/jpy price forecast: jumps towards 144.00 as powell speaks. According to FXStreet on Monday, 30 September, "The USD/JPY remains downward biased despite registering solid gains and climbing above the Tenkan-Sen and Kijun-Sen, each at 143.46 and 143.39, respectively. ", "If USD/JPY breaks above 144.00, the next ceiling level will be 145.00, followed by the 50-day moving average (DMA) at 145.92. "
  • Usd/jpy: bullish momentum on daily chart fades – OCBC. According to FXStreet on Monday, 30 September, "Last Friday, USD/JPY traded up to high of 146.49 after candidate Takaichi managed to get into run-off against Ishiba. ", "We still expect the direction of travel for USD/JPY to be down but the BoJ going for a gradual pace of policy normalisation may see pace of USD/JPY decline slow in the short term. "
  • According to FXStreet on Tuesday, 1 October, "Additionally, the dovish comments from Japan's upcoming Prime Minister, former Defense Chief Shigeru Ishiba, are putting downward pressure on the JPY and underpinning the USD/JPY pair. ", "A break below this level could lead the USD/JPY pair to navigate around the 139.58 region, the lowest point since June 2023."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com